Phase 3 Prevention Trial Showed 81 Reduced Risk Of Symptomatic Sars Cov 2 Infections With Subcutaneous Administration Regen Casirivimab Imdevimab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Apr 12, 2021
TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/
REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week, and 93% in subsequent weeks
Among individuals who developed symptomatic infections, REGEN-COV recipients cleared the virus faster and had much shorter symptom duration
Regeneron will share data with U.S. FDA and request EUA expansion to include COVID prevention for appropriate populations, using a 1,200 mg subcutaneous dose
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 3 trial (2069A) assessing the ability of REGEN-COV™ (casirivimab with imdevimab) to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Inst ....

United States , Myron Cohen , Sarah Cornhill , Georged Yancopoulos , Regeneron Velocimmune , Vesna Tosic , Danh Barouch , National Institute Of Allergy , Regeneron Velocimmune Technology , Teva Pharmaceutical Industries Ltd , University Of North Carolina At Chapel Hill , Prevention Network Co , Department Of Health , Regeneron Pharmaceuticals Inc , National Institutes Of Health , Regeneron Genetics Center , Human Services , Drug Administration , Professor Of Medicine At Harvard Medical School , Exchange Commission , Institute For Global Health Infectious Diseases , National Infusion Center Association , National Institute , Infectious Diseases , National Institutes , Global Health ,